abstract |
Method of predicting whether a patient has a higher probability of benefiting from a treatment with a VEGF antagonist, which comprises screening an isolated sample of said patient for a genomic polymorphism in VEGF (-2578C / A), in which the patient presents a higher probability of benefiting from treatment with a VEGF antagonist if the corresponding genotype comprises VEGF (-2578AA). |